Compare Adaptive Biotechnologies Corp (ADPT) vs iShares iBoxx $ High Yield Corporate Bond ETF (HYG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs iShares iBoxx $ High Yield Corporate Bond ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.01 (market cap $4.04B), while iShares iBoxx $ High Yield Corporate Bond ETF trades at $79.63. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | HYG | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | Fixed Income |
52-Week High | $25.45 | $81.32 |
52-Week Low | $12.30 | $78.72 |
Enterprise Value | $4.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
HYG, the iShares iBoxx $ High Yield Corporate Bond ETF, trades at $79.63 with minimal daily movement (+0.19%). Technical indicators show a bearish trend with moving averages signaling caution, while oscillators remain neutral. Recent news highlights investor rotation into fixed income ETFs amid rising yields, though specific articles question HYG's competitiveness versus peers on expenses and performance.
The outlook for HYG is clouded by bearish technicals and mixed sentiment. Opportunities exist from high-yield demand, but risks include rising interest rates, inflation fears, and underperformance versus alternatives. Investors should weigh the ETF's 6.5% yield against potential downside from economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →
